Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Drugmaker Sues Colorado over First of Its Kind Law Setting Price Ceiling on Drug

Amgen challenges Colorado's drug price cap on Enbrel, citing federal patent law conflicts and due process violations; insurers paid $53,000 on average per patient in 2023.

Summary by 9NEWS Denver
The pharmaceutical company Amgen is suing the Colorado Prescription Drug Affordability Board after the price of one of its drugs was capped.

4 Articles

9NEWS Denver9NEWS Denver
Center

Drugmaker sues Colorado over first of its kind law setting price ceiling on drug

The pharmaceutical company Amgen is suing the Colorado Prescription Drug Affordability Board after the price of one of its drugs was capped.

·Denver, United States
Read Full Article
Denver PostDenver Post
+2 Reposted by 2 other sources
Center

Amgen sues Colorado over state’s first-in-the-nation price ceiling on arthritis drug Enbrel

The drugmaker Amgen has sued Colorado’s Prescription Drug Affordability Board for a second time, alleging that the board’s decision last month to set a price ceiling on Enbrel conflicted with federal law.

·Denver, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Denver Post broke the news in Denver, United States on Monday, November 3, 2025.
Sources are mostly out of (0)

Similar News Topics

Amgen icon

Amgen

Longmont icon

Longmont

News
For You
SearchBlindspotLocal